Seven strategic Flagships spanning the translational pipeline have been established to bring the sector together and collaboratively develop solutions to the most pressing areas of need and make a measurable difference to cardiovascular patient outcomes.
The Flagships provide a platform of strengths from basic research through to clinical care. They are:
Each Flagship is governed by Flagship Director(s) and an Advisory Group. Together, they map exisiting strengths and identify key priorities to deliver greater focus to, and impact from the Australian cardiovascular research effort.
Disease Mechanisms Flagship
Drug Discovery and Translation Flagship
Goal: To create and support a nationwide sustainable ecosystem of drug discovery and translation in Australia that results in a pipeline of therapies to treat cardiac disease, vascular disease and stroke.
Biomedical Engineering Flagship
Goal: To improve and advance the understanding of the mechanisms of cardiovascular disease to deliver practical solutions through the development of new technologies and devices leading to health improvement for individuals, communities and populations.
Precision Medicine Flagship
Goal: To identify the best evidence-based prevention and treatment regimes and programs for implementation and access for all Australians.
Clinical Trials Flagship
Goal: To influence the transformational change needed for successful cardiovascular clinical trials to flourish in Australia.
Big Data Flagship
Goal: To build a coordinated national cardiovascular ‘big data’ platform to drive improvements in health and identify gaps and health inequities in cardiovascular health.
Implementation and Policy Flagship
Goal: To deliver the best cardiovascular care for all Australians, from prevention and primary care through to surgical interventions and to reduce overall healthcare costs to patients and the healthcare system.